Priavoid

Private

DusseldorfHealthcare & Life Scienceshttps://priavoid.com/

Last Round

Grant

Oct 1, 2024

Total Funding Raised

$8.47M

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Priavoid is a biopharmaceutical company developing a novel class of orally available all-D-peptide therapeutics to inhibit and reverse disease-specific protein aggregation in neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Services & Consulting

AI Layer

Non-AI

Keywords

all-d-peptide therapeuticsneurodegenerative disordersAlzheimer's diseaseoligomer detanglertoxic protein oligomersdisease-modifying treatmentclinical-stage biopharmadrug discovery platformamyloid-betaorally available drugParkinson's diseasepeptide therapeuticsprotein misfolding diseasesalpha-synucleintauopathiesblood-brain barrier

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Priavoid Comparables

Compare Priavoid with similar companies based on industry and business-model similarity.

Priavoid comparables — related companies by embedding similarity
Company	Similarity	Market Cap

View Full Comparables Set

Access detailed peer comparisons, similarity scores, and market data.

Priavoid Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Grant	Oct 1, 2024
Series A	Feb 12, 2021

View all Funding Rounds

Key People

Founding team and executive leadership

Philipp Bürling

CEO

Executive Team

Priavoid Investors

Notable investors and investment history

Priavoid investors
Investor	Rounds
Rainwater Charitable Foundation	Grant
Alzheimer's Association	Grant

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Apr 20, 2026
Monthly visitors grew 282% MoM, from 65 to 248.
Jan 16, 2025
Monthly visitors grew 333% MoM, from 199 to 861.

View all signals

Priavoid Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Priavoid Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Priavoid's valuation, stock price, and market status.

Firmographic Details

HeadquartersDusseldorf

Employee Range19

Year Founded2017

Last FundingOct 1, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.